Distinctive In Vivo Kinetics of the New σ1 Receptor Ligands (R)-(+)- and (S)-(–)-18F-Fluspidine in Porcine Brain
Open Access
- 28 July 2014
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 55 (10) , 1730-1736
Abstract
Because of their involvement in growth and survival signaling cascades, the σ1 receptors (σ1Rs) represent a novel target for the treatment of cancer and several brain diseases such as depression and neurodegeneration. From a series of σ1R-specific 18F-fluoroalkylated spirocyclic piperidines, we have chosen 18F-fluspidine for detailed investigation of the in vivo kinetics of the (R)-(+)- and (S)-(–)-enantiomers to identify their potential for imaging in humans. Methods: Enantiopure tosylate precursors for radiolabeling were obtained using chiral preparative high-performance liquid chromatography and used for radiosynthesis of both 18F-fluspidine enantiomers by nucleophilic substitution with K-18F-F-Kryptofix 222-carbonate complex in a synthesis module. Brain pharmacokinetics were investigated by dynamic PET studies in piglets under baseline and blocking conditions using the highly selective σ1R agonist SA4503. Standardized uptake values (SUVs) were calculated for 24 MR-defined brain regions. Total distribution volume (VT) and binding potentials (k3′/k4) of (S)-(–)- and (R)-(+)-18F-fluspidine were estimated. Furthermore, VT values were estimated by graphical analysis using Logan plots. Results: The (S)- and (R)-tosylates were obtained in excellent enantiomeric purities (>98% and >96% enantiomeric excess, respectively). (S)-(–)- and (R)-(+)-18F-fluspidine were synthesized within approximately 70 min (radiochemical yield, 35%–45%; specific activity, 650–870 GBq/μmol; radiochemical purity, >99%). Both radiotracers displayed different brain uptake kinetics. Although the initial brain uptake was similar, the SUV at the end of the study differed significantly (P < 0.05), with (R)-(+)-18F-fluspidine showing about 60%–150% higher values. Administration of SA4503 reduced SUV almost equally for both radiotracers by approximately 65%. Furthermore, k3′ was significantly decreased under blocking conditions in almost all regions ((S)-(–)-18F-fluspidine, −90%–95%; (R)-(+)-18F-fluspidine, −70%–90%) whereas effects on k4 differed according to the particular brain region. VT estimated by both graphical analysis using Logan plots and full nonlinear kinetic analysis revealed significant inhibition for both radiotracers under blocking conditions. Conclusion: Both (S)-(–)- and (R)-(+)-18F-fluspidine appear to be suitable for σ1R imaging in humans. The different pharmacokinetics of (S)-(–)-18F-fluspidine and (R)-(+)-18F-fluspidine may have the potential for application in the diagnostics of different pathologic conditions.Keywords
This publication has 27 references indexed in Scilit:
- Evaluation of σ-1 Receptor Radioligand18F-FTC-146 in Rats and Squirrel Monkeys Using PETJournal of Nuclear Medicine, 2013
- Molecular Imaging of σ1 Receptors In Vivo: Current Status and PerspectivesCurrent Medicinal Chemistry, 2013
- Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depressionProgress in Neurobiology, 2013
- Pharmacological Interaction With the Sigma1 (σ1)-Receptor in the Acute Behavioral Effects of AntidepressantsJournal of Pharmacological Sciences, 2011
- Low density of sigma1 receptors in early Alzheimer’s diseaseAnnals of Nuclear Medicine, 2008
- Function of sigma1 receptors in Parkinson's diseaseActa Neurologica Scandinavica, 2005
- The Role of Sigma Receptors in DepressionJournal of Pharmacological Sciences, 2005
- Differential effects of repeated dl-pentazocine treatment on σ binding sites in discrete brain areas of the ratNeuroscience Letters, 1994
- Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell lossBrain Research, 1993
- p-Chlorophenylalanine-reversible reduction of σ binding sites by chronic imipramine treatment in rat brainEuropean Journal of Pharmacology, 1993